User profiles for Michele Tagliati
Michele TagliatiCaron and Steven D. Broidy Chair and Professor of Neurology, Cedars-Sinai Medical Ctr … Verified email at cshs.org Cited by 13047 |
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues
JM Bronstein, M Tagliati, RL Alterman… - Archives of …, 2011 - jamanetwork.com
Objective: To provide recommendations to patients, physicians, and other health care
providers on several issues involving deep brain stimulation (DBS) for Parkinson disease (PD). …
providers on several issues involving deep brain stimulation (DBS) for Parkinson disease (PD). …
Neurologic manifestations of HIV infection
DM Simpson, M Tagliati - Annals of Internal Medicine, 1994 - acpjournals.org
Purpose: To review the clinical features, pathogenetic mechanisms, and management of
neurologic manifestations of human immunodeficiency virus (HIV) infection. Data Sources: …
neurologic manifestations of human immunodeficiency virus (HIV) infection. Data Sources: …
Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis
Background Parkinson’s disease (PD) is a progressive neurodegenerative movement
disorder frequently associated with a wide variety of non-motor symptoms related to non-…
disorder frequently associated with a wide variety of non-motor symptoms related to non-…
LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
…, E Ohmann, A Deligtisch, M Tagliati… - … England Journal of …, 2006 - Mass Medical Soc
To the Editor: Most cases of Parkinson's disease are considered sporadic and idiopathic,
although there is evidence of familial aggregation, and several monogenic forms have been …
although there is evidence of familial aggregation, and several monogenic forms have been …
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
…, B Guthrie, J Jankovic, R Simpson, M Tagliati… - The Lancet …, 2010 - thelancet.com
Background In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via
an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor …
an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor …
Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers
MS Okun, M Tagliati, M Pourfar… - Archives of …, 2005 - jamanetwork.com
Background Since the Food and Drug Administration approved DBS, there has been a
surge in the number of centers providing the procedure. There is currently no consensus …
surge in the number of centers providing the procedure. There is currently no consensus …
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial
…, KE Lyons, AI Tröster, JL Vitek, M Tagliati - The Lancet …, 2012 - thelancet.com
Background The effects of constant-current deep brain stimulation (DBS) have not been
studied in controlled trials in patients with Parkinson's disease. We aimed to assess the safety …
studied in controlled trials in patients with Parkinson's disease. We aimed to assess the safety …
Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration
IU Isaias, RL Alterman, M Tagliati - Brain, 2008 - academic.oup.com
Pallidal deep brain stimulation (DBS) is currently the most effective treatment for advanced,
medically refractory dystonia. However, factors predicting clinical outcome are not well …
medically refractory dystonia. However, factors predicting clinical outcome are not well …
Deep brain stimulation for primary generalized dystonia: long-term outcomes
IU Isaias, RL Alterman, M Tagliati - Archives of neurology, 2009 - jamanetwork.com
Background Pallidal deep brain stimulation (DBS) is the best therapeutic option for patients
with disabling primary generalized dystonia (PGD) that is refractory to medications. However, …
with disabling primary generalized dystonia (PGD) that is refractory to medications. However, …
Impaired sequence learning in carriers of the DYT1 dystonia mutation
…, M Carbon, G Silvestri, V Dhawan, M Tagliati… - Annals of …, 2003 - Wiley Online Library
Previous positron emission tomography (PET) studies have shown that nonmanifesting
carriers of the DYT1 dystonia mutation express an abnormal pattern of resting glucose …
carriers of the DYT1 dystonia mutation express an abnormal pattern of resting glucose …